Over the past two decades, Texas Retina physicians have participated in more than 100 national clinical trials, offering our patients access to promising new treatments for a variety of retina conditions, including choroidal melanoma, diabetic macular edema, diabetic retinopathy, dry macular degeneration with geographic atrophy, retinal vein occlusion, wet macular degeneration, and uveitis.

We remain committed to conducting ongoing research that will advance retinal care for our patients and recently opened several new clinical trials:

Diabetic Macular Edema

  • Diamond (Dallas Main) — A two-stage, multicenter study of the efficacy and safety of OCS-01 eye drops in subjects with diabetic macular edema.
  • Lotus (Dallas Main) — A study of a novel multivalent fusion antibody (EB-105) in subjects with diabetic macular edema (DME).

Diabetic Retinopathy

  • Glow 2 (Plano) — A Phase III study to evaluate intravitreal tarcocimab tedromer in participants with moderately severe to severe non-proliferative diabetic retinopathy (NPDR).

Dry Age-related Macular Degeneration (AMD) with Geographic Atrophy (GA)

  • Garland (Dallas Main) — An observational Phase IV study to evaluate real-world safety, tolerability, and treatment patterns of pegcetacoplan (Syfovre) in patients with geographic atrophy secondary to age-related macular degeneration.
  • ReGain (Plano) — A Phase III clinical trial to evaluate the efficacy, safety, and pharmacokinetics of subcutaneous injection of elamipretide in subjects who have dry age-related macular degeneration with photoreceptor loss.

Wet Macular Degeneration

  • AIV007-E02 (Plano) — To evaluate the effect of periocularly administered AIV007 gel suspension in subjects with neovascular age-related macular degeneration (nAMD) or diabetic macular edema.
  • OT X-TKI-2023 (Arlington) — A Phase III, parallel-group study to evaluate the efficacy and safety of intravitreal OT X-TKI in subjects with neovascular age-related macular degeneration.


  • Clarity (Plano) — A Phase III study to investigate oral brepocitinib in adults with active, non-infectious intermediate-, posterior-, and panuveitis.

Altogether we currently have 34 open studies. Click here to view our current, actively enrolling clinical trials.

For more information or to determine eligibility for any of these studies, please contact our research department at (214) 692-6885, ext. 1.